help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PARK, S.-H.
Right arrow Articles by MICHEL, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PARK, S.-H.
Right arrow Articles by MICHEL, R. P.

Am. J. Respir. Crit. Care Med., Volume 156, Number 2, August 1997, 600-608

Increased Endothelin-1 in Bleomycin-induced Pulmonary Fibrosis and the Effect of an Endothelin Receptor Antagonist

SUNG-HAE PARK, DINA SALEH, ADEL GIAID, and RENÉ P. MICHEL

Department of Pathology, McGill University, Montréal, Québec, Canada

Idiopathic pulmonary fibrosis (IPF) is characterized by an alveolitis with epithelial and endothelial damage progressing to fibrosis. Numerous mediators have been implicated in this complex process. Studies in humans have shown that endothelin-1 (ET-1), a vasoconstrictor and mitogenic peptide, is a mediator in IPF. To determine the role of ET-1 and endothelin-converting enzyme (ECE)-1 and the effect of bosentan, an ET receptor antagonist, in an animal model of IPF, we studied three groups of rats (n = 6 each): Group 1, control, received saline; Group 2, fibrosis, received 1.5 U bleomycin intratracheally; Group 3, fibrosis-bosentan treated, received bleomycin and bosentan daily by gavage. After 28 d, right upper lobes were fixed for immunohistochemistry (IHC) and sections were stained with antisera to ET-1 and ECE-1 and graded semiquantitatively. Sections from left lungs were embedded in paraffin and stained for light microscopic morphometry to quantitate the fibrosis. By IHC, we found increased ET-1 immunoreactivity (ir) in airway epithelium and inflammatory cells, and ECE-1-ir in airway epithelium, type II pneumocytes and endothelial cells (p < 0.05). By morphometry, the volume fraction (Vv) of connective tissue (CT) increased and the Vv of air decreased in the fibrosis group compared with that in the control group. Bosentan reduced the Vv of CT and increased the Vv of air compared with that in the fibrosis group (p < 0.05). These results indicate that ET-1 is involved in the pathogenesis of pulmonary fibrosis in the rodent model and that blockage of its receptors reduces the fibrosis.




This article has been cited by other articles:


Home page
 Eur Heart JHome page
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J., June 17, 2008; (2008) ehn234v1.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Behr and J. H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Respiratory DiseaseHome page
P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini
Review: New perspectives in the treatment of idiopathic pulmonary fibrosis
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr., J. Behr, K. K. Brown, R. M. du Bois, L. Lancaster, J. A. de Andrade, G. Stahler, I. Leconte, S. Roux, and G. Raghu
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 75 - 81.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
Y. Kamata, M. Iwamoto, and S. Minota
Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller
Lupus, November 1, 2007; 16(11): 901 - 903.
[Abstract] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
K. K. Kim and H. A. Chapman
Endothelin-1 as Initiator of Epithelial-Mesenchymal Transition: Potential New Role for Endothelin-1 during Pulmonary Fibrosis
Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 1 - 2.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis
Endothelin-1 Induces Alveolar Epithelial-Mesenchymal Transition through Endothelin Type A Receptor-Mediated Production of TGF-beta1
Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 38 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Gunther, B. Enke, P. Markart, P. Hammerl, H. Morr, J. Behr, G. Stahler, W. Seeger, F. Grimminger, I. Leconte, et al.
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study
Eur. Respir. J., April 1, 2007; 29(4): 713 - 719.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
O.J. Dempsey, K.M. Kerr, L. Gomersall, H. Remmen, and G.P. Currie
Idiopathic pulmonary fibrosis: an update
QJM, October 1, 2006; 99(10): 643 - 654.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Lebtahi, S. Moreau, S. Marchand-Adam, M.-P. Debray, M. Brauner, P. Soler, J. Marchal, O. Raguin, A. Gruaz-Guyon, J.-C. Reubi, et al.
Increased Uptake of 111In-Octreotide in Idiopathic Pulmonary Fibrosis
J. Nucl. Med., August 1, 2006; 47(8): 1281 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, and G. Simonneau
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
Eur. Heart J., March 1, 2006; 27(5): 589 - 595.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
B. C. Willis, R. M. duBois, and Z. Borok
Epithelial Origin of Myofibroblasts during Fibrosis in the Lung.
Proceedings of the ATS, January 1, 2006; 3(4): 377 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
K. Ask, G. E. M. Martin, M. Kolb, and J. Gauldie
Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls.
Proceedings of the ATS, January 1, 2006; 3(4): 389 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Bouros and K. M. Antoniou
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Eur. Respir. J., October 1, 2005; 26(4): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
N. Khalil and R. O'Connor
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment
Can. Med. Assoc. J., July 20, 2004; 171(2): 153 - 160.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. Sitbon, D. B. Badesch, R. N. Channick, A. Frost, I. M. Robbins, G. Simonneau, V. F. Tapson, and L. J. Rubin
Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension: A 1-Year Follow-up Study
Chest, July 1, 2003; 124(1): 247 - 254.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. W Kenyon and J. M Nappi
Bosentan for the Treatment of Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
R. Shao, Z. Shi, P. J. Gotwals, V. E. Koteliansky, J. George, and D. C. Rockey
Cell and Molecular Regulation of Endothelin-1 Production during Hepatic Wound Healing
Mol. Biol. Cell, June 1, 2003; 14(6): 2327 - 2341.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
N. H.S. Kim and L. J. Rubin
Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2002; 7(1): 9 - 19.
[Abstract] [PDF]

Home page
 NEJMHome page
T. J. Gross and G. W. Hunninghake
Idiopathic Pulmonary Fibrosis
N. Engl. J. Med., August 16, 2001; 345(7): 517 - 525.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. C. Carpenter and K. R. Stenmark
Endothelin receptor blockade decreases lung water in young rats exposed to viral infection and hypoxia
Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L547 - L554.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
P. Teder and P. W. Noble
A Cytokine Reborn? . Endothelin-1 in Pulmonary Inflammation and Fibrosis
Am. J. Respir. Cell Mol. Biol., July 1, 2000; 23(1): 7 - 10.
[Full Text]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
B. Hocher, A. Schwarz, K. A. Fagan, C. Thöne-Reineke, K. El-Hag, H. Kusserow, S. Elitok, C. Bauer, H.-H. Neumayer, D. M. Rodman, et al.
Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice
Am. J. Respir. Cell Mol. Biol., July 1, 2000; 23(1): 19 - 26.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. J. MASON, M. I. SCHWARZ, G. W. HUNNINGHAKE, and R. A. MUSSON
Pharmacological Therapy for Idiopathic Pulmonary Fibrosis . Past, Present, and Future
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1771 - 1777.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society